Browse the evidence

Higher habitual dairy intake does NOT causally affect glycemic traits (fasting glucose, insulin, HbA1c) in adults, despite observational associations.

You do not need to avoid dairy for blood sugar control. The study suggests dairy does not causally affect glycemic traits, so it can be included in a healthy diet without fear of worsening blood sugar levels.

Chronic inflammation, oxidative stress, and gut dysbiosis form a reciprocal triad that perpetuates the pathophysiology of obesity.

Focus on reducing inflammation through diet (anti-inflammatory foods, fiber) and managing stress, as these factors directly impact gut health and oxidative stress, which in turn affect weight regulation.

Reduction of adipocyte-derived SPARC protects against high-fat diet-induced obesity and metabolic dysfunction in female mice by enhancing energy expenditure and lipolysis.

This research identifies SPARC, a protein elevated in obesity, as a key regulator of fat storage. Reducing SPARC (naturally via caloric restriction or potentially via future therapies) may help manage weight by increasing energy expenditure and breaking down fat, particularly in women. While not a direct diet advice, it highlights that lowering this specific protein is linked to improved metabolic health.

SPARC acts as a priming signal for the NLRP3 inflammasome in macrophages, driving chronic inflammation associated with obesity.

Chronic inflammation in obesity is driven by SPARC activating immune cells. Reducing SPARC levels, as seen with weight loss, reduces this inflammation.

GLP1R agonism reduces coronary artery disease (CAD) risk primarily through body weight lowering (BMI) rather than through the reduction of type 2 diabetes (T2D) liability.

If you are using a GLP-1 agonist (like semaglutide or tirzepatide) for heart health, the primary benefit comes from the weight loss it induces, not just from lowering blood sugar. Even if your blood sugar is already well-controlled, the drug's effect on reducing body weight is what significantly lowers your risk of coronary artery disease. This supports using these medications for cardiovascular prevention in obese individuals, regardless of diabetic status.

An intensive, early post-bariatric lifestyle intervention combining nutritional-behavioral tele-counseling and supervised exercise does not improve weight loss or secondary health outcomes compared to standard care alone.

If you have had bariatric surgery, standard post-operative care is likely sufficient for optimal weight loss. Adding an intensive, early lifestyle program with frequent counseling and exercise sessions does not improve results and may be unnecessarily burdensome. Focus on sustainable habits rather than intensive early intervention.

Stimulating the release of endogenous intestinal GIP via K-cell activation reduces food intake and body weight in mice through a central nervous system mechanism.

This research suggests that the hormone GIP, released from the gut after eating, plays a direct role in signaling satiety to the brain. While this is currently demonstrated via genetic manipulation in mice, it implies that therapies enhancing natural GIP release or mimicking its action could help reduce food intake and body weight, potentially offering an alternative or complement to GLP-1 based treatments.

Expert consensus identifies 14 biomarkers of aging suitable for use as outcome measures in human intervention studies, spanning physiological, inflammatory, functional, and epigenetic domains.

When designing an aging intervention study, use one or more of the 14 consensus biomarkers (IGF-1, GDF15, hsCRP, IL-6, muscle mass/strength, grip strength, TUG, gait speed, balance, frailty index, cognitive health, blood pressure, or DNA methylation/epigenetic clocks) as your primary outcome measures. These are validated by expert consensus for detecting changes in biological age.

Blood-based inflammatory biomarkers (IL-6, TNF-α) are suitable for field testing using dry blood spot sampling, unlike DNA methylation-based biomarkers which require advanced laboratory processes.

For field studies, consider using dry blood spot sampling to measure IL-6 and TNF-α, as these can be collected remotely and analyzed, unlike DNA methylation which requires advanced lab processing.

The degree of food processing (classified by NOVA or Poti systems) is not a reliable proxy for nutritional quality, as calorie- and nutrient-dense foods exist across all levels of processing.

Stop assuming that 'ultra-processed' means 'unhealthy' and 'unprocessed' means 'healthy'. Look at the Nutrition Facts table. A highly processed snack might have less sugar and more protein than a minimally processed fruit juice. Base your food choices on the actual calorie and nutrient density, not the processing label.

In Type 1 Diabetes, fracture incidence rates have remained stable or increased in women, despite overall improvements in diabetes management and the adoption of newer technologies.

If you have Type 1 Diabetes, especially if you are a woman, be aware that your fracture risk may not be decreasing as much as it is for Type 2 Diabetes patients. Focus on preventing hypoglycemia, as low blood sugar events are linked to higher fracture risk. Discuss bone health specifically with your endocrinologist.

Compared with animal protein, plant protein results in lower muscle mass, with a stronger negative effect observed in younger adults (<60 years) than in older adults (≥60 years).

If your goal is maximizing muscle mass, animal protein may offer a slight advantage over plant protein, particularly in younger adults. However, the difference is small, and plant protein is still effective. Focus on getting enough total protein and combining plant sources if possible.

There is no significant difference between plant and animal protein for muscle strength or physical performance.

You do not need animal protein to build strength or improve physical performance. Plant protein is equally effective for these outcomes. Focus on consistent training and adequate protein intake.

Post-exercise supplementation with 40g of whey protein provides no additional benefit to cardiorespiratory fitness or cardiometabolic health adaptations compared to an isocaloric placebo when combined with low-volume high-intensity interval training (LOW-HIIT) in sedentary, healthy adults.

If you are sedentary and start doing low-volume high-intensity interval training (HIIT), you do not need to rush to consume 40g of protein immediately after your workout to get the best heart and metabolic health benefits. Consuming an equivalent amount of calories from carbohydrates (like maltodextrin or even just eating a normal meal) provides the same improvements in fitness and blood pressure. Focus on consistency with the training rather than expensive post-workout supplements.

High post-diagnostic consumption of ultra-processed foods (UPFs) is associated with a significantly increased risk of cardiovascular disease (CVD) mortality in patients with stages I–III colorectal cancer (CRC), but not with CRC-specific or all-cause mortality.

For colorectal cancer survivors, reducing ultra-processed food intake (aiming for <3.6 servings/day) is strongly linked to a lower risk of cardiovascular death, which is a major cause of mortality in this group. While this reduction did not show a direct link to preventing cancer recurrence in this study, prioritizing whole foods over processed options supports heart health, a critical component of long-term survivorship.

PPAR agonists (specifically pioglitazone) improve individual histological features of NASH (steatosis, ballooning, inflammation) and can improve fibrosis.

Pioglitazone, a PPAR agonist, improves liver inflammation and fat in NASH patients. It is taken orally (30-45 mg daily). A significant side effect is weight gain (~2.5 kg), which might be undesirable for obese patients. It can also improve fibrosis.

Marketing and promotional strategies in food environments disproportionately target children with unhealthy products, with 97% of products featuring child-directed marketing falling outside healthy dietary guidelines.

Be aware that products marketed to children are overwhelmingly unhealthy. If you are a parent, expect that marketing will drive your child's requests towards these products. Limiting exposure to such marketing and choosing products without child-directed branding can help reduce the influence of these unhealthy options.

In people with diabetes, maintaining an overweight or obese BMI (≥23.0 kg/m²) is associated with a significantly lower risk of major adverse cardiovascular events (MACE) and all-cause mortality compared to a normal-weight BMI (18.5–22.9 kg/m²).

If you have diabetes, do not strive for a 'normal' BMI if it requires losing weight. This study shows that being overweight or obese is associated with lower heart event and death risks compared to being normal weight in diabetic patients. Focus on managing blood sugar and blood pressure rather than weight loss, unless advised otherwise for other reasons. Being underweight is a significant risk factor for mortality.

Targeting the melanocortin-4 receptor (MC4R) with biased agonists that favor Gq/11 signaling over Gs signaling reduces food intake and adiposity without causing adverse cardiovascular effects like hypertension and tachycardia.

If you have a specific genetic form of obesity linked to MC4R, a drug called setmelanotide may help you lose weight and improve glucose tolerance without raising your blood pressure, unlike some older treatments. This is because it targets the specific receptor pathway that controls appetite without triggering the heart-related side effects.

GLP-1RAs exhibit neuroprotective effects and may improve symptoms in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and cognitive dysfunction associated with type 2 diabetes.

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, GLP-1 receptor agonists like semaglutide can significantly reduce heart failure symptoms and improve physical limitations. Additionally, there is emerging evidence that these medications may offer neuroprotective benefits, potentially slowing cognitive decline in patients with T2DM.

Adipose tissue dysfunction, specifically the release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and free fatty acids from visceral fat, drives insulin resistance and beta-cell dysfunction in obesity.

Fat is not just stored energy; it actively sends inflammatory signals that block your body's ability to use insulin. Reducing visceral fat reduces this inflammation, thereby improving insulin sensitivity.

Obesity is significantly underdiagnosed in clinical practice, with less than half of patients with BMI ≥30 receiving a formal ICD-9 diagnosis code, creating a barrier to treatment initiation.

If you have a BMI ≥30, do not assume your provider has formally recognized your obesity. You must actively ask for the diagnosis to be documented in your chart. This formal recognition is often required to unlock insurance coverage for lifestyle interventions, medications, or specialist referrals. Without the ICD-9 code, you may be denied access to effective treatments.

Intentional weight loss is not consistently associated with reduced mortality risk and may increase mortality risk in healthy individuals.

If you are healthy and do not have obesity, intentional weight loss may not reduce your mortality risk and could potentially increase it. Instead, focus on maintaining a healthy lifestyle with regular physical activity and balanced nutrition.

In real-world commercial insurance populations without diabetes, one-year persistence on GLP-1 receptor agonists for obesity treatment is low (32.3%), with significant variation by product, contradicting high persistence rates reported in clinical trials.

If you are using a GLP-1 medication for weight loss, expect that staying on it for a full year is challenging. Real-world data shows only about 1 in 3 people stay on therapy for a year, and this varies by drug. Weekly injections (like semaglutide) tend to have better persistence than daily ones (like liraglutide). Discuss any side effects or supply issues with your doctor immediately rather than stopping abruptly, as discontinuation often leads to weight regain.